Indalo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
Phase 1
Terminated
- Conditions
- Healthy VolunteersIdiopathic Pulmonary Fibrosis
- Interventions
- Drug: PlacebosDrug: IDL-2965 Oral Capsule
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Indalo Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03949530
- Locations
- 🇬🇧
Covance CRU, Leeds, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath